Tran Nguyen
CFO & Chief Strategy Officer at Prothena Corporation
In terms of our 2024 financial performance relative to guidance, we had net cash used in operating and investing activities of $150,300,000 which is at the low end of our guidance range of $148,000,000 to $160,000,000 Net loss was $122,300,000 which is at the low end of our guidance range of $120,000,000 to $135,000,000 As of 12/31/2024, Christina had $472,200,000 in cash, cash equivalents and restricted cash, which is in line with our guidance of $468,000,000 As of 02/20/2025, Christina had approximately 53,800,000.0 ordinary shares outstanding. Additionally, we continue to have a simple capital structure with zero debt. Turning to our 2025 financial guidance on Slide 23, we expect our full year 2025 net cash used in operating and investing activities to be between $168,000,000 and $175,000,000